JERUSALEM (Reuters) – Teva Pharmaceutical Industries will collaborate with French drugmaker Sanofi to develop a treatment for inflammatory bowel disease it hopes will become a blockbuster drug.
Sanofi, a leader in immunology, will invest $1.5 billion in the development of Teva’s anti-TL1A drug, the companies said on Wednesday. The drug is still in phase 2 trials, with interim results not expected until the second half of 2024,
Phase 3 trials are expected to begin in 2025 and Teva chief executive Richard Francis said the best case scenario for the commercial launch of the drug — which will target both Crohn’s disease and ulcerative colitis — would be around 2028.